Genmab A/S
GMAB28.660USD
-0.180-0.62%
Handelsschluss 11/07, 16:00（ET）Kurse um 15 Minuten verzögert
17.65BMarktkapitalisierung
11.91KGV TTM
mehr Informationen über Genmab A/S Unternehmen
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Genmab A/S Informationen
BörsenkürzelGMAB
Name des UnternehmensGenmab A/S
IPO-datumOct 01, 2000
CEODr. Jan G.J. Van De Winkel, Ph.D.
Anzahl der mitarbeiter2682
WertpapierartOrdinary Share
GeschäftsjahresendeOct 01
AddresseCarl Jacobsens Vej 30
StadtVALBY
BörseOMX Nordic Exchange Copenhagen A/S
LandDenmark
Postleitzahl2500
Telefon4570202728
Websitehttps://www.genmab.com/
BörsenkürzelGMAB
IPO-datumOct 01, 2000
CEODr. Jan G.J. Van De Winkel, Ph.D.
Führungskräfte von Genmab A/S
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Ms. Mijke Zachariasse, Ph.D.
Ms. Mijke Zachariasse, Ph.D.
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Ms. Elizabeth A. O'farrell
Ms. Elizabeth A. O'farrell
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Royalties
789.00M
85.30%
Net product sales
101.00M
10.92%
Collaboration revenue
21.00M
2.27%
Reimbursement income
13.00M
1.41%
Milestone payments
1.00M
0.11%
Keine Daten
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Royalties
789.00M
85.30%
Net product sales
101.00M
10.92%
Collaboration revenue
21.00M
2.27%
Reimbursement income
13.00M
1.41%
Milestone payments
1.00M
0.11%
Aktionärsstatistik
Aktualisiert: Sat, Nov 8
Aktualisiert: Sat, Nov 8
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
AllianceBernstein L.P.
1.73%
Orbis Investment Management Ltd.
1.29%
Citadel Advisors LLC
0.58%
Arrowstreet Capital, Limited Partnership
0.56%
Two Sigma Investments, LP
0.56%
Andere
95.28%
Aktionäre
Aktionäre
Anteil
AllianceBernstein L.P.
1.73%
Orbis Investment Management Ltd.
1.29%
Citadel Advisors LLC
0.58%
Arrowstreet Capital, Limited Partnership
0.56%
Two Sigma Investments, LP
0.56%
Andere
95.28%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
4.32%
Investment Advisor
3.18%
Hedge Fund
2.35%
Research Firm
0.64%
Pension Fund
0.03%
Bank and Trust
0.02%
Family Office
0.01%
Andere
89.45%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
515
64.81M
10.54%
-15.68M
2025Q2
501
65.30M
10.31%
-6.21M
2025Q1
515
65.99M
10.42%
-5.32M
2024Q4
512
61.76M
9.33%
+621.44K
2024Q3
493
53.46M
8.41%
-4.14M
2024Q2
495
49.90M
7.86%
-6.30M
2024Q1
501
49.04M
7.53%
-7.16M
2023Q4
490
47.86M
7.32%
-6.37M
2023Q3
479
48.54M
7.43%
+204.98K
2023Q2
467
42.76M
6.55%
-5.77M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
AllianceBernstein L.P.
10.66M
1.73%
-4.06M
-27.59%
Jun 30, 2025
Orbis Investment Management Ltd.
7.92M
1.29%
+2.21M
+38.69%
Jun 30, 2025
Citadel Advisors LLC
3.57M
0.58%
-857.47K
-19.37%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
3.45M
0.56%
+2.08M
+152.25%
Jun 30, 2025
Two Sigma Investments, LP
3.44M
0.56%
-433.92K
-11.20%
Jun 30, 2025
Harding Loevner LP
2.92M
0.48%
+42.61K
+1.48%
Jun 30, 2025
Renaissance Technologies LLC
2.77M
0.45%
+504.40K
+22.30%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.50M
0.41%
-443.29K
-15.04%
Jun 30, 2025
Marshall Wace LLP
1.91M
0.31%
-274.23K
-12.57%
Jun 30, 2025
First Trust Advisors L.P.
1.77M
0.29%
+60.50K
+3.54%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Thu, Nov 6
Aktualisiert: Thu, Nov 6
Name
Anteil
Tema Oncology ETF
5.08%
First Trust NYSE Arca Biotechnology Index Fund
4.45%
WisdomTree BioRevolution Fund
1.33%
iShares Biotechnology ETF
1.32%
AB Disruptors ETF
0.92%
First Trust NASDAQ BuyWrite Income ETF
0.29%
ProShares Ultra Nasdaq Biotechnology
0.13%
Invesco Nasdaq Biotechnology ETF
0.13%
ActivePassive International Equity ETF
0.13%
Avantis International Equity ETF
0.1%
Mehr Anzeigen
Tema Oncology ETF
Anteil5.08%
First Trust NYSE Arca Biotechnology Index Fund
Anteil4.45%
WisdomTree BioRevolution Fund
Anteil1.33%
iShares Biotechnology ETF
Anteil1.32%
AB Disruptors ETF
Anteil0.92%
First Trust NASDAQ BuyWrite Income ETF
Anteil0.29%
ProShares Ultra Nasdaq Biotechnology
Anteil0.13%
Invesco Nasdaq Biotechnology ETF
Anteil0.13%
ActivePassive International Equity ETF
Anteil0.13%
Avantis International Equity ETF
Anteil0.1%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
